Market closedNon-fractional
Lantheus/LNTH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Lantheus
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
Ticker
LNTH
Sector
Healthcare
Trading on
NASDAQ
Industry
Health Care Equipment and Supplies
Headquarters
Bedford, United States
Employees
834
Website
www.lantheus.com
Lantheus Metrics
BasicAdvanced
$7.8B
Market cap
17.38
P/E ratio
$6.50
EPS
0.52
Beta
-
Dividend rate
Price and volume
Market cap
$7.8B
Beta
0.52
Financial strength
Current ratio
4.843
Quick ratio
4.451
Long term debt to equity
66.16
Total debt to equity
66.238
Interest coverage (TTM)
30.96%
Management effectiveness
Return on assets (TTM)
19.01%
Return on equity (TTM)
66.21%
Valuation
Price to earnings (TTM)
17.376
Price to revenue (TTM)
5.667
Price to book
8.32
Price to tangible book (TTM)
10.59
Price to free cash flow (TTM)
28.841
Growth
Revenue change (TTM)
32.98%
Earnings per share change (TTM)
-2,612.58%
3-year revenue growth (CAGR)
58.77%
3-year earnings per share growth (CAGR)
268.38%
What the Analysts think about Lantheus
Analyst Ratings
Majority rating from 11 analysts.
Lantheus Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$370M
4.52%
Net income
$131M
26.82%
Profit margin
35.41%
21.35%
Lantheus Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$1.54
$1.47
$1.75
$1.69
-
Expected
$1.31
$1.32
$1.45
$1.54
$1.82
Surprise
17.52%
11.12%
20.42%
9.48%
-
Lantheus News
AllArticlesVideos
Lantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern Time
GlobeNewsWire·1 week ago
Lantheus Acquires NAV-4694, a Next-Generation ß Amyloid PET Imaging Agent for Alzheimer's Disease
GlobeNewsWire·2 weeks ago
Lantheus Welcomes CMS' Proposed CY25 Rule for Improved Payment for Specialized Diagnostic Radiopharmaceuticals to Support Patient Access
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lantheus stock?
Lantheus (LNTH) has a market cap of $7.8B as of July 27, 2024.
What is the P/E ratio for Lantheus stock?
The price to earnings (P/E) ratio for Lantheus (LNTH) stock is 17.38 as of July 27, 2024.
Does Lantheus stock pay dividends?
No, Lantheus (LNTH) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Lantheus dividend payment date?
Lantheus (LNTH) stock does not pay dividends to its shareholders.
What is the beta indicator for Lantheus?
Lantheus (LNTH) has a beta rating of 0.52. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Lantheus stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.